Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyclo Therapeutics Inc (NQ: CYTH )

1.130 -0.040 (-3.41%)
Streaming Delayed Price Updated: 11:23 AM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cyclo Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
25 Stocks Moving in Wednesday's Pre-Market Session
Gainers 17 Education & Technology Group Inc. (NASDAQ: YQ) rose 283.5% to $3.16 in pre-market trading. 17 Education & Technology, earlier during the month, reported a $10... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Fed Speakers
Pre-open movers U.S. stock futures traded mixed in early pre-market trade after closing mostly flat in the prior session. Investors are awaiting earnings results from Lowe`s... 
Via Benzinga
Topics Economy
Exposures Interest Rates
5 Stocks To Watch For November 17, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Lowe`s Companies Inc (NYSE: LOW) to report quarterly earnings at $2.35 per share on revenue of $... 
Via Benzinga
Cyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common Stock
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Proposed Public Offering of Common Stock
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Shares Jump After Filing To Start Alzheimer's Trial In US
Cyclo Therapeutics Inc (NASDAQ: CYTH) has submitted its initial investigational new drug (IND) application with the FDA for a Phase 2 study of Trappsol Cyclo for... 
Via Benzinga
Exposures Product Safety
Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event
From Cyclo Therapeutics, Inc.
Via Business Wire
JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating... 
From JTC Team, LLC
Via AccessWire
Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimer’s Disease Asset
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM)
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics' Trappsol Shows Early Safety, Efficacy In Genetic Disorder
Cyclo Therapeutics Inc (NASDAQ: CYTH) has announced new data from its Phase 1 extension study evaluating Trappsol Cyclo Niemann-Pick Disease Type C1 (NPC), a... 
Via Benzinga
Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™
From Cyclo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers vTv Therapeutics (NASDAQ:VTVT) shares rose 30.08% to $3.07 during Tuesday's pre-market session. The company's market cap stands at $251.7 million. Adial... 
Via Benzinga
Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Shares Move Higher On Kickstart Of Late-Stage NPC Trial With Trappsol Cyclo
Cyclo Therapeutics Inc (NASDAQ: CYTH) has commenced its pivotal Phase 3 study (TransportNPC) evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1 (NPC1). The... 
Via Benzinga
Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Launch of New Website
From Cyclo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers RAPT Therapeutics (NASDAQ:RAPT) s... 
Via Benzinga
Cyclo Therapeutics Announces Inclusion in the Russell 2000® Index
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference
From Cyclo Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.